Cardium Initiates Phase 2b Excellarate Clinical Study For Diabetic Ulcers

Cardium Therapeutics (AMEX:CXM) and its subsidiary, Tissue Repair Company (TRC) announced the start of recruitment for its Phase 2b clinical trial (MATRIX) to evaluate the safety and efficacy of Excellarate(TM) for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to be administered once or twice to stimulate wound healing. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 18th, 2007